← Back to headlines
REGENXBIO Provides Regulatory Update on RGX-121 for MPS II
REGENXBIO has announced a regulatory update concerning its investigational gene therapy, RGX-121, for the treatment of Mucopolysaccharidosis Type II (MPS II).
24 Aug, 11:49 — 24 Aug, 11:49
Sources
Showing 1 of 1 sources
